<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02314247</url>
  </required_header>
  <id_info>
    <org_study_id>KCP-330-013</org_study_id>
    <nct_id>NCT02314247</nct_id>
  </id_info>
  <brief_title>Efficacy &amp; Safety Study of Selinexor in Relapsed/Refractory Peripheral T-cell Lymphoma &amp; Cutaneous T-cell Lymphoma</brief_title>
  <official_title>Multi-center, Phase II, Open-label Study of Efficacy and Safety of the Selective Inhibitor of Nuclear Export (SINE™) Selinexor (KPT-330) in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) and Cutaneous T-cell Lymphoma (CTCL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karyopharm Therapeutics Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karyopharm Therapeutics Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-arm, multi-center, open-label Phase II study of the SINE™ compound Selinexor
      given orally to patients with relapsed/refractory PTCL and CTCL.

      Approximately 60 patients with relapsed or refractory PTCL and CTCL who meet the eligibility
      criteria and have none of the exclusion criteria will be enrolled to receive Selinexor until
      either disease progression or intolerance has occurred.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-arm, multi-center, open-label Phase II study of the SINE™ compound selinexor
      given orally to patients with relapsed/refractory PTCL and CTCL.

      Approximately 60 patients with relapsed or refractory PTCL and CTCL who meet the eligibility
      criteria and have none of the exclusion criteria will be enrolled to receive Selinexor until
      either disease progression or intolerance has occurred.

      Enrolled patients will be given Selinexor at an oral fixed 60 mg dose (equivalent to ~35
      mg/m2) on Days 1 and 3 of Weeks 1-4 of each 4-week cycle. There is no maximum treatment
      duration.

      Patients will receive supportive therapy to mitigate Selinexor side effects, as well as best
      supportive care (BSC).
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Due to enrollment challenges. The termination is not a consequence of any safety concern.
  </why_stopped>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Peripheral T-cell Lymphoma (PTCL)</condition>
  <condition>Cutaneous T-cell Lymphoma (CTCL)</condition>
  <arm_group>
    <arm_group_label>Selinexor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 mg dose (equivalent to ~35 mg/m2)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Selinexor</intervention_name>
    <description>20 mg oral tablets: Oral 60 mg dose on Days 1 and 3 of Weeks 1-4 of each 4-week cycle. Number of Cycles: up to 12 but there is no maximal duration for treatment.</description>
    <arm_group_label>Selinexor</arm_group_label>
    <other_name>KPT-330</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ECOG performance status of ≤2

          -  Relapsed or refractory disease to at least one prior systemic regimen.

          -  Measurable disease: according to IWC for all PTCL and according to CTCL Response in
             Skin consensus criteria for all CTCL patients

          -  Objective, documented evidence of disease progression on study entry

        Exclusion Criteria:

          -  Known active central nervous system (CNS) lymphoma

          -  Active graft-versus-host disease after allogeneic stem cell transplantation. At least
             4 months must have elapsed since completion of allogeneic stem cell transplantation

          -  Unable to swallow capsules or malabsorption syndrome, disease significantly affecting
             gastrointestinal function.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Kauffman, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Karyopharm Therapeutics Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Concord Hospital</name>
      <address>
        <city>Concord</city>
        <state>New South Wales</state>
        <zip>2139</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal North Shore Hospital</name>
      <address>
        <city>St. Leonards</city>
        <state>New South Wales</state>
        <zip>2139</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabrini Hospital</name>
      <address>
        <city>Malvern</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inje University Busan Paik Hospital</name>
      <address>
        <city>Busan</city>
        <zip>614-735</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Centre</name>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Korea, Republic of</country>
    <country>Singapore</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 3, 2014</study_first_submitted>
  <study_first_submitted_qc>December 8, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2014</study_first_posted>
  <last_update_submitted>January 22, 2018</last_update_submitted>
  <last_update_submitted_qc>January 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PTCL</keyword>
  <keyword>CTCL</keyword>
  <keyword>Peripheral T-cell Lymphoma</keyword>
  <keyword>Cutaneous T-cell Lymphoma</keyword>
  <keyword>Karyopharm</keyword>
  <keyword>KPT-330</keyword>
  <keyword>Selinexor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Peripheral</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Cutaneous</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

